Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

13.3%

2 terminated out of 15 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

27%

4 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed with results

Key Signals

2 with results75% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (2)
P 1 (1)
P 2 (8)
P 3 (2)
P 4 (2)

Trial Status

Completed6
Active Not Recruiting3
Recruiting3
Terminated2
Unknown1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07441395Phase 2Recruiting

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07216027Phase 2Active Not Recruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT06436183Phase 2Completed

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT05642208Phase 4Active Not Recruiting

Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

NCT06855745Phase 2Recruiting

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

NCT06554847Phase 3Active Not Recruiting

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

NCT05732454Phase 2Terminated

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05575882Not ApplicableRecruiting

Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.

NCT05003453Phase 2CompletedPrimary

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

NCT05913791Not ApplicableUnknownPrimary

Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema

NCT00671528Phase 4Terminated

Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

NCT03568136Phase 2Completed

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

NCT03175354Phase 2Completed

A Study in Subjects With Moderate Atopic Dermatitis

NCT03050151Phase 1Completed

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT00560378Phase 3Completed

Long-term Safety of Protopic in Atopic Eczema

Showing all 15 trials

Research Network

Activity Timeline